Reply to: Can circulating <scp>CD34</scp>+ cells count be used for the prognosis of myelofibrosis? Probably yes, at least in patients treated with ruxolitinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Reply to: Can circulating CD34+ cells count be used for the prognosis of myelofibrosis? Probably yes, at least in patients treated with ruxolitinib

Published:2023-01-04 Issue:6 Volume:200 Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Iurlo Alessandra¹^ORCID,Galli Nicole¹²,Bucelli Cristina¹,Artuso Silvia¹,Consonni Dario³,Cattaneo Daniele¹²

Affiliation:

1. Hematology Division Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milan Italy

2. Department of Oncology and Hemato‐Oncology University of Milan Milan Italy

3. Epidemiology Unit Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milan Italy

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18641

Reference6 articles.

1. Can circulating CD34+ cell count be used for the prognosis of myelofibrosis?;Zhang Y.;Br J Haematol,2022

2. Trend of circulating CD34 ⁺ cells in patients with myelofibrosis: Association with spleen response during ruxolitinib treatment

3. Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia

4. Transient elastography spleen stiffness measurements in primary myelofibrosis patients: a pilot study in a single centre

5. The ISHAGE Guidelines for CD34+ Cell Determination by Flow Cytometry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP